Physician profile
Julie B Burnham
NPI 1336246966
$836,306.88
in general payments reported to CMS, 2019-2025
74 companies · $100K in 2025
The $100K reported for 2025 was more than what 98% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $231K · 2020: $79K · 2021: $99K · 2022: $99K · 2023: $109K · 2024: $117K · 2025: $100K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $256K · Travel and Lodging: $26K · Food and Beverage: $24K · Consulting Fee: $19K · Honoraria: $1,580 · Education: $284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $256,051.25 |
| Travel and Lodging | $25,797.45 |
| Food and Beverage | $23,845.36 |
| Consulting Fee | $19,366.00 |
| Honoraria | $1,580.00 |
| Education | $284.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $239,102.68 | 2019-2025 | Mavenclad, Mavenclad |
| Genzyme Corporation | $184,557.62 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $90,872.75 | 2019-2025 | Ultomiris, Soliris |
| Amgen INC. | $77,565.19 | 2019-2025 | Uplizna, Aimovig |
| Abbvie INC. | $53,261.11 | 2019-2025 | Ubrelvy, Qulipta, Duopa |
| Genentech USA, INC. | $39,735.14 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Teva Pharmaceuticals USA, INC. | $30,326.32 | 2019-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Tg Therapeutics, INC. | $23,863.63 | 2023-2025 | |
| Merck Kgaa | $18,287.21 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $16,169.36 | 2020-2022 | |
| Celgene Corporation | $15,667.65 | 2019-2025 | Zeposia |
| Novartis Pharmaceuticals Corporation | $7,530.52 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $7,189.67 | 2022 | |
| Pfizer INC. | $5,381.44 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $5,277.40 | 2021 |
Show all 74 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $4,018.04 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $2,767.53 | 2020-2022 | |
| Ucb, INC. | $2,251.64 | 2019-2025 | Nayzilam, Briviact, Rystiggo |
| Lundbeck LLC | $2,082.07 | 2019-2025 | Vyepti, Rexulti |
| Biogen, INC. | $1,291.03 | 2019-2025 | Tysabri, Vumerity, Skyclarys |
| Sanofi-Aventis U.S. LLC | $832.52 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $739.72 | 2023-2025 | Purified Cortrophin Gel |
| Avanir Pharmaceuticals, INC. | $725.38 | 2019-2022 | |
| Neurelis, INC. | $560.89 | 2020-2025 | Valtoco |
| Neurocrine Biosciences, INC. | $463.57 | 2020-2025 | Ingrezza, Ongentys |
| Eisai INC. | $444.76 | 2019-2025 | |
| Kyowa Kirin, INC. | $417.44 | 2020-2025 | Nourianz |
| Supernus Pharmaceuticals, INC. | $350.58 | 2019-2024 | Qelbree |
| Argenx US, INC. | $339.55 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Sunovion Pharmaceuticals INC. | $333.18 | 2019-2021 | |
| Acorda Therapeutics, INC | $284.47 | 2019-2023 | Inbrija |
| Otsuka America Pharmaceutical, INC. | $270.44 | 2023-2025 | Nuedexta, Rexulti |
| Acadia Pharmaceuticals INC | $269.21 | 2019-2025 | Nuplazid |
| Amneal Pharmaceuticals LLC | $268.90 | 2019-2023 | Rytary |
| Upsher-Smith Laboratories LLC | $228.18 | 2020-2023 | |
| Lilly USA, LLC | $225.60 | 2019-2025 | Kisunla, Amyvid |
| Genentech, INC. | $224.45 | 2023-2025 | Enspryng, Ocrevus |
| Horizon Therapeutics Plc | $187.15 | 2021-2023 | Uplizna |
| Adamas Pharmaceuticals, INC. | $174.18 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $158.46 | 2023-2024 | Aptiom |
| Corium, LLC | $143.71 | 2022-2023 | Adlarity |
| Catalyst Pharmaceuticals, INC. | $141.76 | 2020-2024 | Fycompa |
| Banner Life Sciences, LLC | $105.33 | 2021 | |
| Vanda Pharmaceuticals INC. | $93.37 | 2025 | Ponvory |
| Mdd US Operations, LLC | $87.31 | 2021-2024 | Apokyn, Gocovri |
| Ge Healthcare | $85.84 | 2019-2024 | |
| Greenwich Biosciences, INC. | $83.64 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $75.20 | 2022-2025 | |
| Sk Life Science, INC. | $64.89 | 2020-2022 | |
| Janssen Biotech, INC. | $61.00 | 2025 | |
| Azurity Pharmaceuticals, INC. | $50.21 | 2023-2024 | Horizant, Horizant |
| Nevro Corp. | $49.60 | 2022-2024 | Senza |
| Astrazeneca Pharmaceuticals Lp | $45.95 | 2021-2024 | |
| Arbor Pharmaceuticals, INC. | $43.91 | 2019-2021 | |
| Vertical Pharmaceuticals, LLC | $40.94 | 2019 | |
| Assertio Therapeutics, INC. | $33.77 | 2020 | |
| Avion Pharmaceuticals | $33.11 | 2023 | Dhivy |
| Cycle Pharmaceuticals INC | $32.24 | 2025 | Tascenso Odt, Bafiertam |
| Strongbridge US INC. | $29.36 | 2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $28.98 | 2025 | Rexulti |
| Alnylam Pharmaceuticals INC. | $28.55 | 2019 | |
| Mallinckrodt Hospital Products INC. | $26.64 | 2022 | |
| Tanabe Pharma America, INC. | $26.15 | 2025 | Radicava |
| Owp Pharmaceuticals, INC. | $22.39 | 2025 | Subvenite |
| Livanova USA, INC. | $22.36 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Akcea Therapeutics, INC. | $22.31 | 2020 | |
| Averitas Pharma INC. | $21.04 | 2023 | Qutenza |
| Aprecia Pharmaceuticals, LLC | $20.90 | 2022 | |
| Axsome Therapeutics, INC. | $17.70 | 2025 | Symbravo |
| Csl Behring | $16.72 | 2025 | Hizentra |
| Nobelpharma America, LLC | $16.24 | 2023 | |
| Harmony Biosciences LLC | $14.12 | 2020 | |
| Zogenix INC. | $12.60 | 2021 | |
| Promius Pharma LLC | $12.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Burnham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.